Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Adv Exp Med Biol. 2008;615:127-58. doi: 10.1007/978-1-4020-6554-5_7.

Trail receptors: targets for cancer therapy.

Author information

  • 1Human Genome Sciences, Oncology Research Department, Rockville, MD 20850, USA. robin_humphreys@hgsi.com

Abstract

A human tumor cell's ability to avoid the normal regulatory mechanisms of cell growth, division, and death are the hallmarks of transformation and cancer. Numerous novel therapeutic agents currently in preclinical or clinical evaluation aim to revive the normal regulation or evade these regulatory defects and induce growth arrest and cell death. One of the cell death pathways that has garnered significant interest, as a potential target for therapeutic intervention, is the programmed cell death pathway regulated by the tumor necrosis factor-related apoptosis-inducing ligand receptors (TRAIL-RS). Receptor agonist molecules including forms of the native ligand and monoclonal antibodies are being developed and tested as therapeutics in the treatment of human cancer.

PMID:
18437894
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk